M. N. Tereshin, A. M. Komyakova, V. N. Stepanenko, I. V. Myagkikh, N. S. Shoshina, Yu. V. Korolkova, E. V. Leychenko, S. A. Kozlov, “Optimized method for the recombinant production of a sea anemone’s peptide”, Mendeleev Commun., 2022, Volume 32, Issue 6,Pages <nobr>745–746</nobr>

RUS ENG

JOURNALS // Mendeleev Communications // Archive

Mendeleev Commun., 2022 Volume 32, Issue 6, Pages 745–746 (Mi mendc785)

This article is cited in 2 papers

Communications

Optimized method for the recombinant production of a sea anemone’s peptide

M. N. Tereshin^ab, A. M. Komyakova^a, V. N. Stepanenko^a, I. V. Myagkikh^a, N. S. Shoshina^a, Yu. V. Korolkova^a, E. V. Leychenko^cd, S. A. Kozlov^a

^a M.M. Shemyakin–Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation
^b M.V. Lomonosov Institute of Fine Chemical Technologies, MIREA - Russian Technological University, Moscow, Russian Federation
^c G.B. Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch of the Russian Academy of Sciences, Vladivostok, Russian Federation
^d Far Eastern Federal University, Vladivostok, Russian Federation

Abstract: The production of the analgesic peptide HCRG21 for medical use is restricted by a number of limitations in the technology. The optimal biotechnological method scalable to industrial has been developed based on the production of a fusion protein containing a special leader, His-tag, and Smt3 sequence upstream in the peptide sequence. The resulting peptide shared its inhibitory activity to TRPV1 ion channel identical to the published early.

Keywords: analgesic peptide, biotechnology, SUMO fusion, production in prokaryotes, fluorescence imaging, TRPV1 ion channel.

Language: English

DOI: 10.1016/j.mencom.2022.11.012

Fulltext: PDF file (730 kB)
Cited by

	*Supplementary materials:*
		Supplementary_data_1.pdf	652.4 Kb

© Steklov Math. Inst. of RAS, 2025